Healthcare Roundup – LabCorp to offer free COVID-19 blood tests, OPKO Health EPS beats by $0.13

医疗保健精选——LabCorp提供免费COVID-19血液检测,OPKO Health每股盈利增长
Published on: July 31, 2020
Author: Amy Liu

LabCorp to offer free COVID-19 blood tests

According to a post on social media, LabCorp (LH +0.3%) is about to announce that it will offer free COVID-19 blood tests to anyone through their doctor. Its only request is a donation of plasma from those having antibodies.

OPKO Health EPS beats by $0.13, beats on revenue

OPKO Health (NASDAQ:OPK): Q2 GAAP EPS of $0.05 beats by $0.13.

Revenue of $301.2M (+33.0% Y/Y) beats by $71.72M.

Shares +4%.

Aimmune Therapeutics EPS beats by $0.03

Aimmune Therapeutics (NASDAQ:AIMT): Q2 Non-GAAP EPS of -$0.81; GAAP EPS of -$1.06 beats by $0.03.

Cash, equivalents and investments of $318M.

Gilead Sciences EPS misses by $0.34, misses on revenue

Gilead Sciences (NASDAQ:GILD): Q2 Non-GAAP EPS of $1.11 misses by $0.34; GAAP EPS of -$2.66 misses by $1.79.

Revenue of $5.14B (-9.7% Y/Y) misses by $160M.

Shares -0.9%.

AbbVie Q2 2020 Earnings Preview

AbbVie (NYSE:ABBV) is scheduled to announce Q2 earnings results on Friday, July 31st, before market open.

The consensus EPS Estimate is $2.20 (-2.7% Y/Y) and the consensus Revenue Estimate is $10.14B (+22.8% Y/Y).

The company had guided its Q2 adj. operating margin of ~47.5%.

Over the last 2 years, ABBV has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.

Over the last 3 months, EPS estimates have seen 3 upward revisions and 5 downward. Revenue estimates have seen 6 upward revisions and 1 downward.

Biotechnology Healthcare Services Life Science Medical Device Pharmaceutical